Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
03/20/18 7:19 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Mar 6 2018
Summary ToggleAdverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
- Feb 26 2018
Summary ToggleAdverum Biotechnologies to Present at Upcoming Investor Conferences
- Feb 26 2018
Summary ToggleAdverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiency
- Feb 12 2018
Summary ToggleAdverum Biotechnologies Announces Closing of $69 Million Public Offering
There are currently no events to display.